Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform
On June 3, Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform without a price target.
Blueprint Medicines Corp (BPMC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 3,850,000 | $340,763,500 | +225% | 5.32% |
| 2. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,007,569 | $89,179,932 | -9% | 5.1% |
| 3. | Alkeon Capital Management Panayotis Takis Sparaggis | 900,628 | $79,714,585 | +13% | 0.17% |
| 4. | Hood River Capital Management David Swank | 900,205 | $79,677,145 | +3% | 1.36% |
| 5. | Siren L.L.C. Raymond Debbane | 726,167 | $64,273,041 | 3.63% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.98 | 1,100 | 92,281 | 2022-11-03 | Filing | ||
| $82.66 | 10 | 5,822 | 2021-07-13 | Filing | ||
| $59.98 | 5,000 | 10,812 | 2022-03-03 | Filing | ||
| $18.00 | 125,000 | Large Shareholder, Other | 2,500,711 | 2015-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $127.88 | 2,418 | 54,206 | 2025-06-03 | Filing | ||
| $127.88 | 241 | 56,624 | 2025-06-03 | Filing | ||
| $101.93 | 650 | 146,630 | 2025-05-27 | Filing | ||
| $101.02 | 4,350 | 147,280 | 2025-05-27 | Filing | ||
| $101.72 | 57 | 64,718 | 2025-05-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,710,708 | $593,964,767 | 0.01% | |
| 2. | 6,640,523 | $587,752,692 | 0.01% | |
| 3. | 3,073,306 | $272,018,314 | 0.05% | |
| 4. | 2,684,117 | $237,571,196 | 0.01% | |
| 5. | 2,506,514 | $221,851,604 | 0.02% |
News See All
Stephens & Co. Downgrades Blueprint Medicines (BPMC) to Equal Weight, Cuts PT
On June 3, Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from Overweight, slashing the price target to $135 from $150.
Blueprint Medicines Corporation (BPMC) Downgraded at TD Cowen
This modification comes after Sanofi declared its intention to buy Blueprint Medicines Corporation (NASDAQ:BPMC).
Wolfe Research Lowered Blueprint Medicines Corporation (BPMC) from Outperform to Peer Perform
This happened after Sanofi announced plans to buy the company for $9.1 billion in stock value and up to $9.5 billion in contingent value rights.
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript May 1, 2025Blueprint Medicines Corporation misses on earnings expectations.
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
Billionaire Hedge Funds
